Top

Published in:

01-09-2016 | Original Article

Plasma exosomal miR-21 and miR-181a differentiates follicular from papillary thyroid cancer

Authors: Roman Samsonov, Vladimir Burdakov, Tatiana Shtam, Zamira Radzhabovа, Dmitry Vasilyev, Evgenia Tsyrlina, Sergey Titov, Michail Ivanov, Lev Berstein, Michael Filatov, Nikolay Kolesnikov, Hava Gil-Henn, Anastasia Malek

Published in: Tumor Biology | Issue 9/2016

Abstract

Thyroid cancer (TC) is the most common endocrine malignancy and its incidence has increased over the last few decades. As has been revealed by a number of studies, TC tissue’s micro-RNA (miRNA) profile may reflect histological features and the clinical behavior of tumor. However, alteration of the miRNA profile of plasma exosomes associated with TC development has to date not been explored. We isolated exosomes from plasma and assayed their characteristics using laser diffraction particle size analysis, atomic force microscopy, and western blotting. Next, we profiled cancer-associated miRNAs in plasma exosomes obtained from papillary TC patients, before and after surgical removal of the tumor. The diagnostic value of selected miRNAs was evaluated in a large cohort of patients displaying different statuses of thyroid nodule disease. MiRNA assessment was performed by RT-qPCR. In total, 60 patients with different types of thyroid nodal pathology were included in the study. Our results revealed that the development of papillary TC is associated with specific changes in exosomal miRNA profiles; this phenomenon can be used for differential diagnostics. MiRNA-31 was found to be over-represented in the plasma exosomes of patients with papillary TC vs. benign tumors, while miRNA-21 helped to distinguish between benign tumors and follicular TC. MiRNA-21 and MiRNA-181a-5p were found to be expressed reciprocally in the exosomes of patients with papillary and follicular TC, and their comparative assessment may help to distinguish between these types of TC with 100 % sensitivity and 77 % specificity.

Gharib H. Changing trends in thyroid practice: understanding nodular thyroid disease. Endocr Pract. 2004;10(1):31–9. doi:10.4158/EP.10.1.31.CrossRefPubMed

Dean DS, Gharib H. Epidemiology of thyroid nodules. Best Pract Res Clin Endocrinol Metab. 2008;22(6):901–11. doi:10.1016/j.beem.2008.09.019.CrossRefPubMed

Kato MA, Fahey 3rd TJ. Molecular markers in thyroid cancer diagnostics. Surg Clin North Am. 2009;89(5):1139–55. doi:10.1016/j.suc.2009.06.012.CrossRefPubMed

Wang CC, Friedman L, Kennedy GC, Wang H, Kebebew E, Steward DL, et al. A large multicenter correlation study of thyroid nodule cytopathology and histopathology. Thyroid. 2011;21(3):243–51. doi:10.1089/thy.2010.0243.CrossRefPubMedPubMedCentral

Yip L, Kelly L, Shuai Y, Armstrong MJ, Nikiforov YE, Carty SE, et al. MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Ann Surg Oncol. 2011;18(7):2035–41. doi:10.1245/s10434-011-1733-0.CrossRefPubMed

Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol. 2014;9:287–314. doi:10.1146/annurev-pathol-012513-104715.CrossRefPubMed

http://www.rosettagenomics.com/.

Lee JC, Gundara JS, Glover A, Serpell J, Sidhu SB. MicroRNA expression profiles in the management of papillary thyroid cancer. Oncologist. 2014;19(11):1141–7. doi:10.1634/theoncologist.2014-0135.CrossRefPubMedPubMedCentral

Cancer Genome Atlas Research N. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159(3):676–90. doi:10.1016/j.cell.2014.09.050.CrossRef

10.

Dettmer MS, Perren A, Moch H, Komminoth P, Nikiforov YE, Nikiforova MN. MicroRNA profile of poorly differentiated thyroid carcinomas: new diagnostic and prognostic insights. J Mol Endocrinol. 2014;52(2):181–9. doi:10.1530/JME-13-0266.CrossRefPubMedPubMedCentral

11.

Zhang Y, Zhong Q, Chen X, Fang J, Huang Z. Diagnostic value of microRNAs in discriminating malignant thyroid nodules from benign ones on fine-needle aspiration samples. Tumour Biol. 2014;35(9):9343–53. doi:10.1007/s13277-014-2209-1.CrossRefPubMed

12.

Schwarzenbach H, Nishida N, Calin GA, Pantel K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol. 2014;11(3):145–56. doi:10.1038/nrclinonc.2014.5.CrossRefPubMed

13.

Yu S, Liu Y, Wang J, Guo Z, Zhang Q, Yu F, et al. Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2012;97(6):2084–92. doi:10.1210/jc.2011-3059.CrossRefPubMed

14.

Lee JC, Zhao JT, Clifton-Bligh RJ, Gill A, Gundara JS, Ip JC, et al. MicroRNA-222 and microRNA-146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer. Cancer. 2013;119(24):4358–65. doi:10.1002/cncr.28254.CrossRefPubMed

15.

Cantara S, Pilli T, Sebastiani G, Cevenini G, Busonero G, Cardinale S, et al. Circulating miRNA95 and miRNA190 are sensitive markers for the differential diagnosis of thyroid nodules in a Caucasian population. J Clin Endocrinol Metab. 2014;99(11):4190–8. doi:10.1210/jc.2014-1923.CrossRefPubMed

16.

Lee YS, Lim YS, Lee JC, Wang SG, Park HY, Kim SY, et al. Differential expression levels of plasma-derived miR-146b and miR-155 in papillary thyroid cancer. Oral Oncol. 2015;51(1):77–83. doi:10.1016/j.oraloncology.2014.10.006.CrossRefPubMed

17.

Sato-Kuwabara Y, Melo SA, Soares FA, Calin GA. The fusion of two worlds: non-coding RNAs and extracellular vesicles—diagnostic and therapeutic implications (review). Int J Oncol. 2015;46(1):17–27. doi:10.3892/ijo.2014.2712.PubMed

18.

Chen WX, Cai YQ, Lv MM, Chen L, Zhong SL, Ma TF, et al. Exosomes from docetaxel-resistant breast cancer cells alter chemosensitivity by delivering microRNAs. Tumour Biol. 2014;35(10):9649–59. doi:10.1007/s13277-014-2242-0.CrossRefPubMed

19.

Hannafon BN, Carpenter KJ, Berry WL, Janknecht R, Dooley WC, Ding WQ. Exosome-mediated microRNA signaling from breast cancer cells is altered by the anti-angiogenesis agent docosahexaenoic acid (DHA). Mol Cancer. 2015;14:133. doi:10.1186/s12943-015-0400-7.CrossRefPubMedPubMedCentral

20.

Melo SA, Sugimoto H, O’Connell JT, Kato N, Villanueva A, Vidal A, et al. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell. 2014;26(5):707–21. doi:10.1016/j.ccell.2014.09.005.CrossRefPubMedPubMedCentral

21.

Ogata-Kawata H, Izumiya M, Kurioka D, Honma Y, Yamada Y, Furuta K, et al. Circulating exosomal microRNAs as biomarkers of colon cancer. PLoS One. 2014;9(4):e92921. doi:10.1371/journal.pone.0092921.CrossRefPubMedPubMedCentral

22.

Fujita Y, Kuwano K, Ochiya T, Takeshita F. The impact of extracellular vesicle-encapsulated circulating microRNAs in lung cancer research. BioMed Res Int. 2014;2014:486413. doi:10.1155/2014/486413.CrossRefPubMedPubMedCentral

23.

Que R, Ding G, Chen J, Cao L. Analysis of serum exosomal microRNAs and clinicopathologic features of patients with pancreatic adenocarcinoma. World J Surg Oncol. 2013;11:219. doi:10.1186/1477-7819-11-219.CrossRefPubMedPubMedCentral

24.

Zoller M. Pancreatic cancer diagnosis by free and exosomal miRNA. World J Gastrointest Pathophysiol. 2013;4(4):74–90. doi:10.4291/wjgp.v4.i4.74.CrossRefPubMedPubMedCentral

25.

Whiteside TL. The potential of tumor-derived exosomes for noninvasive cancer monitoring. Expert Rev Mol Diagn. 2015;1293:310.

26.

Lee JC, Zhao JT, Gundara J, Serpell J, Bach LA, Sidhu S. Papillary thyroid cancer-derived exosomes contain miRNA-146b and miRNA-222. J Surg Res. 2015;196(1):39–48. doi:10.1016/j.jss.2015.02.027.CrossRefPubMed

27.

Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman F, et al. A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol. 2009;10(6):R64. doi:10.1186/gb-2009-10-6-r64.CrossRefPubMedPubMedCentral

28.

Benes V, Castoldi M. Expression profiling of microRNA using real-time quantitative PCR, how to use it and what is available. Methods. 2010;50(4):244–9. doi:10.1016/j.ymeth.2010.01.026.CrossRefPubMed

29.

Ferraz C, Lorenz S, Wojtas B, Bornstein SR, Paschke R, Eszlinger M. Inverse correlation of miRNA and cell cycle-associated genes suggests influence of miRNA on benign thyroid nodule tumorigenesis. J Clin Endocrinol Metab. 2013;98(1):E8–16. doi:10.1210/jc.2012-2564.CrossRefPubMed

30.

Suresh R, Sethi S, Ali S, Giorgadze T, Sarkar FH. Differential expression of MicroRNAs in papillary thyroid carcinoma and their role in racial disparity. J Cancer Sci Ther. 2015;7(5):145–54. doi:10.4172/1948-5956.1000340.PubMedPubMedCentral

31.

Xiong Y, Kotian S, Zeiger MA, Zhang L, Kebebew E. miR-126-3p inhibits thyroid cancer cell growth and metastasis, and is associated with aggressive thyroid cancer. PLoS One. 2015;10(8):e0130496. doi:10.1371/journal.pone.0130496.CrossRefPubMedPubMedCentral

32.

Boufraqech M, Zhang L, Jain M, Patel D, Ellis R, Xiong Y, et al. miR-145 suppresses thyroid cancer growth and metastasis and targets AKT3. Endocr Relat Cancer. 2014;21(4):517–31. doi:10.1530/ERC-14-0077.CrossRefPubMed

33.

Gu Y, Li D, Luo Q, Wei C, Song H, Hua K, et al. MicroRNA-145 inhibits human papillary cancer TPC1 cell proliferation by targeting DUSP6. Int J Clin Exp Med. 2015;8(6):8590–8.PubMedPubMedCentral

34.

Acunzo M, Romano G, Wernicke D, Croce CM. MicroRNA and cancer—a brief overview. Adv Biol Regul. 2015;57:1–9. doi:10.1016/j.jbior.2014.09.013.CrossRefPubMed

35.

Kosaka N. Decoding the secret of cancer by means of extracellular vesicles. J Clin Med. 2016;5(2). doi:10.3390/jcm5020022.

36.

Swierniak M, Wojcicka A, Czetwertynska M, Stachlewska E, Maciag M, Wiechno W, et al. In-depth characterization of the microRNA transcriptome in normal thyroid and papillary thyroid carcinoma. J Clin Endocrinol Metab. 2013;98(8):E1401–9. doi:10.1210/jc.2013-1214.CrossRefPubMed

37.

Nikiforova MN, Tseng GC, Steward D, Diorio D, Nikiforov YE. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab. 2008;93(5):1600–8. doi:10.1210/jc.2007-2696.CrossRefPubMedPubMedCentral

38.

Agretti P, Ferrarini E, Rago T, Candelieri A, De Marco G, Dimida A, et al. MicroRNA expression profile helps to distinguish benign nodules from papillary thyroid carcinomas starting from cells of fine-needle aspiration. Eur J Endocrinol. 2012;167(3):393–400. doi:10.1530/EJE-12-0400.CrossRefPubMed

39.

Whiteside TL. The potential of tumor-derived exosomes for noninvasive cancer monitoring. Expert Rev Mol Diagn. 2015;15(10):1293–310. doi:10.1586/14737159.2015.1071666.CrossRefPubMedPubMedCentral

40.

Lowry MC, Gallagher WM, O’Driscoll L. The role of exosomes in breast cancer. Clin Chem. 2015;61(12):1457–65. doi:10.1373/clinchem.2015.240028.CrossRefPubMed

41.

Taverna S, Giallombardo M, Gil-Bazo I, Carreca AP, Castiglia M, Chacartegui J, et al. Exosomes isolation and characterization in serum is feasible in non-small cell lung cancer patients: critical analysis of evidence and potential role in clinical practice. Oncotarget. 2016. 10.18632/oncotarget.7638.

42.

Chevillet JR, Kang Q, Ruf IK, Briggs HA, Vojtech LN, Hughes SM, et al. Quantitative and stoichiometric analysis of the microRNA content of exosomes. Proc Natl Acad Sci U S A. 2014;111(41):14888–93. doi:10.1073/pnas.1408301111.CrossRefPubMedPubMedCentral

43.

Koga K, Matsumoto K, Akiyoshi T, Kubo M, Yamanaka N, Tasaki A, et al. Purification, characterization and biological significance of tumor-derived exosomes. Anticancer Res. 2005;25(6A):3703–7.PubMed

44.

Lozupone F, Kont V, Logozzi A, Talpsepp K, Oja T, Kubo A, et al. TM9SF4 level of expression on exosomes as new marker of malignancy in human cancer. First scientific meeting of ISEV-International Society for Extracellular Vesicles April 18-21 2012. Gothenburg: University of Gothenburg; 2012. p. 19.

45.

Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2015;523(7559):177–82. doi:10.1038/nature14581.CrossRefPubMedPubMedCentral

46.

Ferracin M, Lupini L, Salamon I, Saccenti E, Zanzi MV, Rocchi A, et al. Absolute quantification of cell-free microRNAs in cancer patients. Oncotarget. 2015;6(16):14545–55.CrossRefPubMedPubMedCentral

47.

Madhavan B, Yue S, Galli U, Rana S, Gross W, Muller M, et al. Combined evaluation of a panel of protein and miRNA serum-exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity. Int J Cancer. 2015;136(11):2616–27. doi:10.1002/ijc.29324.CrossRefPubMed

48.

Aragon Han P, Weng CH, Khawaja HT, Nagarajan N, Schneider EB, Umbricht CB, et al. MicroRNA expression and association with clinicopathologic features in papillary thyroid cancer: a systematic review. Thyroid. 2015. doi:10.1089/thy.2015.0193.PubMed

49.

Dettmer M, Perren A, Moch H, Komminoth P, Nikiforov YE, Nikiforova MN. Comprehensive MicroRNA expression profiling identifies novel markers in follicular variant of papillary thyroid carcinoma. Thyroid. 2013;23(11):1383–9. doi:10.1089/thy.2012.0632.CrossRefPubMedPubMedCentral

Title: Plasma exosomal miR-21 and miR-181a differentiates follicular from papillary thyroid cancer
Authors: Roman Samsonov
Vladimir Burdakov
Tatiana Shtam
Zamira Radzhabovа
Dmitry Vasilyev
Evgenia Tsyrlina
Sergey Titov
Michail Ivanov
Lev Berstein
Michael Filatov
Nikolay Kolesnikov
Hava Gil-Henn
Anastasia Malek
Publication date: 01-09-2016
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 9/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-016-5065-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2016

Aphanin, a triterpenoid from Amoora rohituka inhibits K-Ras mutant activity and STAT3 in pancreatic carcinoma cells

High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer

Silencing of ZRF1 impedes survival of estrogen receptor positive MCF-7 cells and potentiates the effect of curcumin

Synergistic increase in efficacy of a combination of 2-deoxy-d-glucose and cisplatin in normoxia and hypoxia: switch from autophagy to apoptosis

DUSP28 links regulation of Mucin 5B and Mucin 16 to migration and survival of AsPC-1 human pancreatic cancer cells

The clinical significance of changes in ezrin expression in osteosarcoma of children and young adults

Keynote webinar | Spotlight on antibody–drug conjugates in cancer